Moreover, targeting the CDK4 pathway has emerged as a therapeutic approach for patients with BRAF-mutant metastatic melanomas.349 A patient-centered translational study has shown improved clinical outcomes for individuals with stage III or stage IV metastatic BRAF and NRAS wild-type melanoma who do not respond to standard therapy, typically immunotherapy. Here, BRAF is linked to melanoma.